Series C funding sends Biofourmis to near-unicorn status
Add BT as a preferred source
Singapore
HOMEGROWN startup Biofourmis has raised US$100 million in a Series C equity round led by Softbank Vision Fund 2, catapulting the healthcare company to near-unicorn status in a matter of months.
The latest funding, which sources said has quadrupled Biofourmis' valuation from about US$200 million previously, comes despite a slowdown in healthcare investments in the Asia-Pacific over the first half of the year.
TRENDING NOW
On the board but frozen out: The Taib family feud tearing Sarawak construction giant apart
Thai and Vietnamese farmers may stop planting rice because of the Iran war. Here’s why
PayPal plans job cuts as its new CEO pursues turnaround strategy
MAS, bank CEOs convene over AI cyberthreats; boards told to own risks, not leave to IT teams
